Xun Gui
YOU?
Author Swipe
View article: Blockchain-Enabled Identity Based Authentication Scheme for Cellular Connected Drones
Blockchain-Enabled Identity Based Authentication Scheme for Cellular Connected Drones Open
The proliferation of drones across precision agriculture, disaster response operations, and delivery services has accentuated the critical need for secure communication frameworks. Due to the limited computational capabilities of drones an…
View article: Overcoming multidrug resistance in gastrointestinal cancers with a CDH17-targeted ADC conjugated to a DNA topoisomerase inhibitor
Overcoming multidrug resistance in gastrointestinal cancers with a CDH17-targeted ADC conjugated to a DNA topoisomerase inhibitor Open
Cadherin 17 (CDH17) has emerged as a promising target for gastrointestinal (GI) cancers, which are often complicated by multidrug resistance (MDR) and recurrence. In this study, we developed 7MW4911, a CDH17-targeted antibody-drug conjugat…
View article: Cardiolipin-mimic lipid nanoparticles without antibody modification delivered senolytic in vivo CAR-T therapy for inflamm-aging
Cardiolipin-mimic lipid nanoparticles without antibody modification delivered senolytic in vivo CAR-T therapy for inflamm-aging Open
View article: IL-11/IL-11R signal inhibition by 9MW3811 remodels immune tumor microenvironment and enhances anti-tumor efficacy of PD-1 blockade
IL-11/IL-11R signal inhibition by 9MW3811 remodels immune tumor microenvironment and enhances anti-tumor efficacy of PD-1 blockade Open
Recent studies have uncovered evidences for pro-tumorigenic activities attributed to IL-11, prompting a renewed focus on therapeutic strategies targeting IL-11 signaling for anti-tumor treatment. Here, we introduce 9MW3811, a monoclonal an…
View article: Specifically blocking αvβ8-mediated TGF-β signaling to reverse immunosuppression by modulating macrophage polarization
Specifically blocking αvβ8-mediated TGF-β signaling to reverse immunosuppression by modulating macrophage polarization Open
View article: Cardiolipin-mimic lipid nanoparticles without antibody modification delivered senolytic in-vivo CAR-T therapy for inflamm-aging
Cardiolipin-mimic lipid nanoparticles without antibody modification delivered senolytic in-vivo CAR-T therapy for inflamm-aging Open
mRNA-based in vivo CAR T cell engineering offers advantages over ex vivo therapies, including streamlined manufacturing and transient expression. However, current delivery requires antibody-modified vehicles with manufacturing challenges. …
View article: Preclinical development of a novel CCR8/CTLA-4 bispecific antibody for cancer treatment by disrupting CTLA-4 signaling on CD8 T cells and specifically depleting tumor-resident Tregs
Preclinical development of a novel CCR8/CTLA-4 bispecific antibody for cancer treatment by disrupting CTLA-4 signaling on CD8 T cells and specifically depleting tumor-resident Tregs Open
Anti-CTLA-4 antibodies faced challenges due to frequent adverse events and limited efficacy, which spurred the exploration of next-generation CTLA-4 therapeutics to balance regulatory T cells (Tregs) depletion and CD8 T cells activation. C…
View article: Data from LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development
Data from LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development Open
The existing T cell–centered immune checkpoint blockade therapies have been successful in treating some but not all patients with cancer. Immunosuppressive myeloid cells, including myeloid-derived suppressor cells (MDSC), that inhibit anti…
View article: Supplementary Fig. 2 from LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development
Supplementary Fig. 2 from LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development Open
Supplementary Fig. 2 with figure legend
View article: Supplementary Fig. 1A from LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development
Supplementary Fig. 1A from LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development Open
Supplementary Fig. 1A with figure legend
View article: Supplementary Fig. 1B from LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development
Supplementary Fig. 1B from LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development Open
Supplementary Fig. 1A with figure legend
View article: Data from LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development
Data from LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development Open
The existing T cell–centered immune checkpoint blockade therapies have been successful in treating some but not all patients with cancer. Immunosuppressive myeloid cells, including myeloid-derived suppressor cells (MDSC), that inhibit anti…
View article: Supplementary Fig. 1B from LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development
Supplementary Fig. 1B from LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development Open
Supplementary Fig. 1A with figure legend
View article: Supplementary Tables from LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development
Supplementary Tables from LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development Open
Supplementary Tables 1-4
View article: Supplementary Fig. 1C from LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development
Supplementary Fig. 1C from LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development Open
Supplementary Fig. 1C with figure legend
View article: Supplementary Fig. 1A from LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development
Supplementary Fig. 1A from LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development Open
Supplementary Fig. 1A with figure legend
View article: Supplementary Fig. 1C from LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development
Supplementary Fig. 1C from LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development Open
Supplementary Fig. 1C with figure legend
View article: Supplementary Tables from LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development
Supplementary Tables from LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development Open
Supplementary Tables 1-4
View article: Supplementary Fig. 3 from LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development
Supplementary Fig. 3 from LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development Open
Supplementary Fig. 3 with figure legend
View article: Supplementary Fig. 3 from LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development
Supplementary Fig. 3 from LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development Open
Supplementary Fig. 3 with figure legend
View article: Supplementary Fig. 2 from LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development
Supplementary Fig. 2 from LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development Open
Supplementary Fig. 2 with figure legend
View article: Supplementary Fig. 1D from LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development
Supplementary Fig. 1D from LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development Open
Supplementary Fig. 1D with figure legend
View article: Supplementary Fig. 1D from LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development
Supplementary Fig. 1D from LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development Open
Supplementary Fig. 1D with figure legend
View article: Research on Government Data Sharing Mechanism Based on Smart Contracts
Research on Government Data Sharing Mechanism Based on Smart Contracts Open
Exploring mechanisms for internal data sharing within government departments is important in advancing digital and intelligent society. This paper is based on the establishment of decentralized nodes on the external network of government d…
View article: LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development
LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development Open
The existing T cell–centered immune checkpoint blockade therapies have been successful in treating some but not all patients with cancer. Immunosuppressive myeloid cells, including myeloid-derived suppressor cells (MDSC), that inhibit anti…
View article: Fc gamma receptors promote antibody-induced LILRB4 internalization and immune regulation of monocytic AML
Fc gamma receptors promote antibody-induced LILRB4 internalization and immune regulation of monocytic AML Open
The immune checkpoint leukocyte immunoglobulin-like receptor B4 (LILRB4) is found specifically on the cell surface of acute monocytic leukemia (monocytic AML), an aggressive and common subtype of AML. We have developed a humanized monoclon…
View article: Data from Disrupting LILRB4/APOE Interaction by an Efficacious Humanized Antibody Reverses T-cell Suppression and Blocks AML Development
Data from Disrupting LILRB4/APOE Interaction by an Efficacious Humanized Antibody Reverses T-cell Suppression and Blocks AML Development Open
Therapeutic strategies are urgently needed for patients with acute myeloid leukemia (AML). Leukocyte immunoglobulin-like receptor B4 (LILRB4), which suppresses T-cell activation and supports tissue infiltration of AML cells, represents an …
View article: Figure S5 from Disrupting LILRB4/APOE Interaction by an Efficacious Humanized Antibody Reverses T-cell Suppression and Blocks AML Development
Figure S5 from Disrupting LILRB4/APOE Interaction by an Efficacious Humanized Antibody Reverses T-cell Suppression and Blocks AML Development Open
h128-3 blocks AML THP-1 cells tissue infiltration in a time-dependent manner.
View article: Figure S3 from Disrupting LILRB4/APOE Interaction by an Efficacious Humanized Antibody Reverses T-cell Suppression and Blocks AML Development
Figure S3 from Disrupting LILRB4/APOE Interaction by an Efficacious Humanized Antibody Reverses T-cell Suppression and Blocks AML Development Open
Schematic diagram of the LILRB4 chimeric receptor reporter system.
View article: Table S1 from Disrupting LILRB4/APOE Interaction by an Efficacious Humanized Antibody Reverses T-cell Suppression and Blocks AML Development
Table S1 from Disrupting LILRB4/APOE Interaction by an Efficacious Humanized Antibody Reverses T-cell Suppression and Blocks AML Development Open
Data collection and refinement statistics.